QCLS

SEC source: 0001493152-26-045586 · ownership.xml · nonDerivative · entry 2

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,845

F2 · price: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

SEC source: 0001493152-26-045586 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,455

F1 · price: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

SEC source: 0001493152-26-045576 · ownership.xml · derivative · entry 2

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-04-13

F2 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-045576 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,835

F1 · security: Represents a grant of RSUs issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026.

F1 · price: Represents a grant of RSUs issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026.

F3 · balance_after: Amount Beneficially Owned Following Transaction has been corrected from 262,191 to 116,835.

SEC source: 0001493152-26-016910 · ownership.xml · derivative · entry 1

Friscia Stephen · CIK 0002028845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-04-13

F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-016911 · ownership.xml · derivative · entry 1

Glass Mitchell · CIK 0002023649 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-04-13

F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-016914 · ownership.xml · derivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-04-13

F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-016913 · ownership.xml · derivative · entry 1

Voss Chelsea Sierra · CIK 0002108237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-04-13

F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-016912 · ownership.xml · derivative · entry 2

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 100,000 shares

Expires 2036-04-13

F2 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-016912 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,191

F1 · price: Represents a grant of Restricted Stock Units ("RSUs") issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026.

SEC source: 0001493152-26-016909 · ownership.xml · derivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-04-13

F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.

SEC source: 0001493152-26-023217 · ownership.xml · nonDerivative · entry 1

Voss Chelsea Sierra · CIK 0002108237 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Roth IRA

Disclosed balance after: 61,555

SEC source: 0001493152-26-004565 · ownership.xml · derivative · entry 4

Voss Chelsea Sierra · CIK 0002108237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,500

Underlying: Common Stock · 212,500 shares

Expires 2036-01-16

F3 · derivative.exercise_date: The stock options were granted pursuant to the Consulting Agreement and will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is employed by or providing services to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: The stock options were granted pursuant to the Consulting Agreement and will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is employed by or providing services to the Issuer through the applicable vesting dates.

SEC source: 0001493152-26-004565 · ownership.xml · nonDerivative · entry 2

Voss Chelsea Sierra · CIK 0002108237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,900

F2 · price: Represents a grant of RSUs issued in connection with the appointment of the Reporting Person as director of the Issuer's board of directors. The RSUs will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is employed by or providing services to the Issuer through the applicable vesting dates.

SEC source: 0001493152-26-004565 · ownership.xml · nonDerivative · entry 1

Voss Chelsea Sierra · CIK 0002108237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,900

F1 · price: Represents a grant of Restricted Stock Units ("RSUs") issued pursuant to a consulting agreement, dated January 16, 2026, by and between the Issuer and the Reporting Person (the "Consulting Agreement"). The RSUs will vest in four substantially equal installments on each quarterly anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer through the applicable vesting dates.

SEC source: 0001493152-25-023699 · ownership.xml · nonDerivative · entry 1

Friscia Stephen · CIK 0002028845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001493152-25-023697 · ownership.xml · nonDerivative · entry 1

Bernstein Bruce · CIK 0001665472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001493152-25-023701 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,029

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001493152-25-023696 · ownership.xml · nonDerivative · entry 1

RAUCH GARY M · CIK 0001597530 · Vice President of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001493152-25-023937 · ownership.xml · nonDerivative · entry 1

Glass Mitchell · CIK 0002023649 · Director · Director, Chief Medical Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001493152-25-023936 · ownership.xml · nonDerivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,024

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance.

SEC source: 0001683168-25-008517 · ownership.xml · derivative · entry 2

PharmaCyte Biotech, Inc. · CIK 0001157075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 889,865

Underlying: Common stock, par value $0.001 per share · 889,865 shares

Expires 2030-11-14

F1 · derivative.exercise_price: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · date: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · price: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · derivative.exercise_date: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

SEC source: 0001493152-25-017129 · ownership.xml · nonDerivative · entry 1

Friscia Stephen · CIK 0002028845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,161

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.

SEC source: 0001493152-25-017130 · ownership.xml · nonDerivative · entry 1

Glass Mitchell · CIK 0002023649 · Director · Director, Chief Medical Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,080

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.

SEC source: 0001493152-25-017133 · ownership.xml · nonDerivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,185

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.

SEC source: 0001493152-25-017132 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,673

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.

SEC source: 0001493152-25-017131 · ownership.xml · nonDerivative · entry 1

RAUCH GARY M · CIK 0001597530 · Vice President of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,080

F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025.

SEC source: 0001683168-25-008517 · ownership.xml · derivative · entry 1

PharmaCyte Biotech, Inc. · CIK 0001157075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 889,865

Underlying: Common stock, par value $0.001 per share · 889,865 shares

Expires not disclosed

F1 · derivative.exercise_price: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · date: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · price: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · derivative.exercise_date: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

F1 · derivative.expiration_date: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

SEC source: 0001641172-25-005424 · ownership.xml · derivative · entry 1

Glass Mitchell · CIK 0002023649 · Director · President, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2035-04-16

F1 · derivative.expiration_date: The stock options are subject to expiration if the employment of the Reporting Person is terminated.

SEC source: 0001641172-25-005426 · ownership.xml · derivative · entry 1

RHODES IAN · CIK 0001612365 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-04-16

F1 · derivative.expiration_date: The stock options are subject to expiration if the employment of the Reporting Person is terminated.

SEC source: 0001641172-25-005425 · ownership.xml · derivative · entry 1

RAUCH GARY M · CIK 0001597530 · Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-04-16

F1 · derivative.expiration_date: The stock options are subject to expiration if the employment of the Reporting Person is terminated.

SEC source: 0001493152-23-030111 · ownership.xml · nonDerivative · entry 1

Rivard Paul · CIK 0001857479 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001493152-23-029445 · ownership.xml · nonDerivative · entry 1

Rivard Paul · CIK 0001857479 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

SEC source: 0001493152-23-020794 · ownership.xml · derivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020795 · ownership.xml · derivative · entry 1

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020793 · ownership.xml · derivative · entry 1

Kaplin Adam · CIK 0001858042 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020799 · ownership.xml · derivative · entry 1

Uzonwanne Jude · CIK 0001858040 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020796 · ownership.xml · derivative · entry 1

Schreiber Christopher C · CIK 0001750076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020798 · ownership.xml · derivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020797 · ownership.xml · derivative · entry 1

EAGLE CRAIG · CIK 0001562135 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 475,000

Underlying: Common Stock · 475,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-020800 · ownership.xml · derivative · entry 1

Rivard Paul · CIK 0001857479 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-23-011040 · ownership.xml · derivative · entry 1

Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2028-04-04

F1 · derivative.exercise_date: The stock options vest as follows: (i) 250,000 on the date of grant; (ii) 250,000 on the first anniversary of the date of grant; and (iii) 250,000 on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.

SEC source: 0001493152-22-034969 · ownership.xml · nonDerivative · entry 1

Rivard Paul · CIK 0001857479 · EVP of Operations, GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.53, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 3

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,775

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.70, inclusive.

SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 2

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,775

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.17, inclusive.

SEC source: 0001493152-21-029973 · ownership.xml · nonDerivative · entry 1

Silverman Joshua · CIK 0001524858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,509

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.97 to $6.96, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.

SEC source: 0001493152-21-029774 · ownership.xml · nonDerivative · entry 1

Rivard Paul · CIK 0001857479 · EVP of Operations, GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.97 to $6.05, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001493152-21-025608 · ownership.xml · derivative · entry 1

White Billy Joe · CIK 0001546805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025613 · ownership.xml · derivative · entry 1

Kaplin Adam · CIK 0001858042 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

SEC source: 0001493152-21-025609 · ownership.xml · derivative · entry 1

Schreiber Christopher C · CIK 0001750076 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company").

F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.

F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control.